Abstract: A method for distinguishing between gray matter and white matter starting from a time-dependent computed tomography image data record from a perfusion CT examination is disclosed. In at least one embodiment, a plurality of time-independent images are calculated from the time-dependent image data record, a plurality of threshold histogram analyses are performed in order to determine regions of the brain which can be assigned to one or more types of cerebral matter, and subsequently the region of gray matter is determined from the information obtained in respect of type and region of the cerebral matter using at least one logical combination and at least one exclusion method. A control and computational unit is also disclosed with a storage medium in which a computer program or program module is stored, which executes the described method during operation.

Abstract: A method for distinguishing between gray matter and white matter starting from a time-dependent computed tomography image data record from a perfusion CT examination is disclosed. In at least one embodiment, a plurality of time-independent images are calculated from the time-dependent image data record, a plurality of threshold histogram analyses are performed in order to determine regions of the brain which can be assigned to one or more types of cerebral matter, and subsequently the region of gray matter is determined from the information obtained in respect of type and region of the cerebral matter using at least one logical combination and at least one exclusion method. A control and computational unit is also disclosed with a storage medium in which a computer program or program module is stored, which executes the described method during operation.

Abstract: In order to compare a left and a right half of the brain of a patient on the basis of medical 2D or 3D image data records for determining the perfusion, the brain of the patient is subdivided into brain regions, wherein the number of brain regions is an even number n, a number n/2 of the brain regions being arranged in the right half of the brain and a number n/2 of the brain regions being arranged in the left half of the brain, with each of the brain regions arranged in the right half of the brain being unambiguously assigned to a brain region arranged in the left half of the brain, and the brain being subdivided by planes standing perpendicularly on a median sagittal plane. In at least one embodiment, the image data records are segmented, wherein brain image data records are generated which only include those picture elements of the image data records which represent the brain of the patient.

Abstract: Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012?1×1013 vector genomes/ml.

Abstract: Provided are methods for the identification of novel genes involved in a variety of cellular processes, including retinal degeneration, retinal disease, cancer, memory and learning, amylotropic lateral sclerosis, and methods for the identification of the function of a variety of genes and gene fragments of unknown function. The genes thus identified, as well as the compositions used in the identification methods, are also provided.

Abstract: Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012–1×1013 vector genomes/ml.

Abstract: Disclosed are serotype-specific recombinant adeno-associated viral (rAAV) vectors, as well as viral particles and compositions comprising them, useful in the expression of neurotherapeutic agents (including neurotherapeutic peptides and polypeptides) in selected mammalian neural cells, as well as tissues and organ systems comprising them. In particular embodiments, rAAV serotype 1 and serotype 5 vectors are disclosed useful for the delivery of therapeutic agents to neural cells of affected mammals.

Abstract: Disclosed are methods for the use of neprilysin-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian neprilysin polypeptides is described. Also disclosed are medicaments and methods for the treatment and amelioration of symptoms of a variety of conditions and neprilysin deficiencies in an animal, including, for example, Alzheimer's disease, and related disorders, as well as neurological and musculoskeletal disorders, including for example, diseases caused by the accumulation of ?-amyloid protein in the cells and tissues of affected animals.

Abstract: Vectors that encode Adeno-Associated Virus (AAV) Rep and Cap proteins of different serotypes and Adenovirus transcription products that provide helper functions were used to produce pseudotyped recombinant AAV (rAAV) virions. Purification methods generated pseudotyped rAAV virion stocks that were 99% pure with titers of 1×1012-1×1013 vector genomes/ml.